Navigation Links
Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
Date:9/1/2010

were held across 90 centers in 7 countries.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin has completed two Phase III clinical trials for the non-surgical treatment of retinal disorders. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long acting anti-coagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

For further information please contact: ThromboGenics Dr. Steve Pakola, CMO Tel: +1(212)201-0920 steve.pakola@thrombogenics.com
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
4. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
5. SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
6. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
9. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
10. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
11. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Quorum Review IRB, the industry ... large clinical trials called Quick Step™ . The offering ... address the research industry’s need for seamless study start-up with ... available for studies planning 50 or more North American investigator ... North American site count of 80 or more. Qualifying studies ...
(Date:7/22/2014)... Biofeedback – When a behavioral problem ... medication to best treat it can become a matter ... electroencephalography (EEG) can help predict which medicine will offer ... adverse drug events. , The article “Medication Prediction ... issue of the journal Biofeedback offers evidence that quantitative ...
(Date:7/21/2014)... IL (PRWEB) July 21, 2014 ... and simple programming, the new Cole-Parmer® Digital ... is easy to operate for automated process ... for hands-free dispensing. The batch count function counts ... volume or totalizer tracks amount dispensed across multiple ...
(Date:7/21/2014)... , July 21, 2014  Mike Patterson, CEO ... $1.6 million in Series Seed B funding to ... sensors for the life science, defense, intelligence, and ... Partners led the round and was joined by ... Said Patterson , "This round of funding ...
Breaking Biology Technology:Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3New Easy-View Cole-Parmer Digital Gear Pump Drive Makes Performance Monitoring Effortless 2Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology 2
... (Nasdaq: WHRT, TSX:,WHT) Since January 2008, ... various financing alternatives to raise additional,capital, including ... order to continue operations. At April 30, ... of approximately $0.5 million and,current liabilities of ...
... Barr Pharmaceuticals,Inc. (NYSE: BRL ) today ... final approval from the U.S. Food and Drug,Administration ... to,manufacture and market a generic version of Yasmin(R) ... and marketed,by Bayer Schering Pharma, AG., On ...
... KENILWORTH, N.J., May 9 Schering-Plough,Corporation (NYSE: SGP ... 16, 2008, in Memphis, Tenn. At 8 a.m. (CDT) ... the meeting will be available to all interested,parties via ... the Annual Meeting, Fred Hassan, Chairman and CEO, will ...
Cached Biology Technology:WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting 2WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting 3WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting 4Barr Announces Approval of Generic Yasmin(R) 2Barr Announces Approval of Generic Yasmin(R) 3
(Date:7/22/2014)... challenges faced by researchers in modifying properties of nanomaterials ... simple technique, thanks to recent innovative studies conducted by ... Through the use of a simple, efficient and low ... research teams, led by Professor Sow Chorng Haur from ... Science, demonstrated that the properties of two different types ...
(Date:7/22/2014)... cost-effectiveness analysis of commercial diet programs and pills, the ... best value for the money. The Jenny Craig regimen ... most expensive option tested, according to researchers at Duke-National ... findings, published in the June issue of the journal ... and weight-loss benefits per dollar spent as insurance carriers ...
(Date:7/22/2014)... NY -- As part of a multinational, collaborative effort, ... Sinai have helped identify over 100 locations in the ... in the largest genomic study published on any psychiatric ... published online in Nature , point to biological ... lead to new approaches to treating the disorder, which ...
Breaking Biology News(10 mins):NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3Mount Sinai scientists and international team shed new light on schizophrenia 2Mount Sinai scientists and international team shed new light on schizophrenia 3
... New combinations of agents based on the oldest synthetic ... spread of malaria parasites and make a significant contribution ... "Roll Back Malaria Initiative." In a study on 160 ... medicine from the Heidelberg University Hospital have shown that ...
... Wash. -- Some researchers hope to turn plants into ... this, scientists have to learn how to convert plant ... cheaply and efficiently. In new research, chemists have successfully ... directly into the building block called HMF in one ...
... Individuals with heart disease are twice as likely to ... the medical community has largely been unable to explain. ... Hospital, in conjunction with The Montral Heart Institute, University ... genetic variations that contribute to depression in heart disease ...
Cached Biology News:Old stain in a new combination 2Old stain in a new combination 3Plastic that grows on trees, part two 2Genetic factors may predict depression in heart disease patients 2Genetic factors may predict depression in heart disease patients 3
... T Squareds patented high efficiency dynamic valve ... With the most compact, lightweight package in ... use in portable air and gas applications., ... high efficiency. , Includes DC Motor. ...
...
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
Biology Products: